Pegylated interferon alfa-2a: Difference between revisions
No edit summary |
Gloria Picoy (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
{{DrugProjectFormSinglePage | |||
|authorTag={{GP}} | |||
|genericName=Pegylated interferon alfa-2a | |||
|aOrAn=an | |||
|drugClass=alfa interferon | |||
|blackBoxWarningTitle=<b><span style="color:#FF0000;">TITLE</span></b> | |||
|blackBoxWarningBody=<i><span style="color:#FF0000;">Condition Name:</span></i> (Content) | |||
|offLabelAdultGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of Pegylated interferon alfa-2a in adult patients. | |||
|offLabelAdultNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of Pegylated interferon alfa-2a in adult patients. | |||
|offLabelPedGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of Pegylated interferon alfa-2a in pediatric patients. | |||
|offLabelPedNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of Pegylated interferon alfa-2a in pediatric patients. | |||
|alcohol=Alcohol-Pegylated interferon alfa-2a interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication. | |||
}} | |||
__NOTOC__ | __NOTOC__ | ||
{{Pegylated interferon alfa-2a}} | {{Pegylated interferon alfa-2a}} | ||
Revision as of 19:20, 4 February 2015
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Gloria Picoy [2]
Disclaimer
WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.
Overview
Pegylated interferon alfa-2a is an alfa interferon that is FDA approved for the {{{indicationType}}} of {{{indication}}}. Common adverse reactions include {{{adverseReactions}}}.
Adult Indications and Dosage
FDA-Labeled Indications and Dosage (Adult)
There is limited information regarding Pegylated interferon alfa-2a FDA-Labeled Indications and Dosage (Adult) in the drug label.
Off-Label Use and Dosage (Adult)
Guideline-Supported Use
There is limited information regarding Off-Label Guideline-Supported Use of Pegylated interferon alfa-2a in adult patients.
Non–Guideline-Supported Use
There is limited information regarding Off-Label Non–Guideline-Supported Use of Pegylated interferon alfa-2a in adult patients.
Pediatric Indications and Dosage
FDA-Labeled Indications and Dosage (Pediatric)
There is limited information regarding Pegylated interferon alfa-2a FDA-Labeled Indications and Dosage (Pediatric) in the drug label.
Off-Label Use and Dosage (Pediatric)
Guideline-Supported Use
There is limited information regarding Off-Label Guideline-Supported Use of Pegylated interferon alfa-2a in pediatric patients.
Non–Guideline-Supported Use
There is limited information regarding Off-Label Non–Guideline-Supported Use of Pegylated interferon alfa-2a in pediatric patients.
Contraindications
There is limited information regarding Pegylated interferon alfa-2a Contraindications in the drug label.
Warnings
There is limited information regarding Pegylated interferon alfa-2a Warnings' in the drug label.
Adverse Reactions
Clinical Trials Experience
There is limited information regarding Pegylated interferon alfa-2a Clinical Trials Experience in the drug label.
Postmarketing Experience
There is limited information regarding Pegylated interferon alfa-2a Postmarketing Experience in the drug label.
Drug Interactions
There is limited information regarding Pegylated interferon alfa-2a Drug Interactions in the drug label.
Use in Specific Populations
Pregnancy
Pregnancy Category (FDA):
There is no FDA guidance on usage of Pegylated interferon alfa-2a in women who are pregnant.
Pregnancy Category (AUS):
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Pegylated interferon alfa-2a in women who are pregnant.
Labor and Delivery
There is no FDA guidance on use of Pegylated interferon alfa-2a during labor and delivery.
Nursing Mothers
There is no FDA guidance on the use of Pegylated interferon alfa-2a in women who are nursing.
Pediatric Use
There is no FDA guidance on the use of Pegylated interferon alfa-2a in pediatric settings.
Geriatic Use
There is no FDA guidance on the use of Pegylated interferon alfa-2a in geriatric settings.
Gender
There is no FDA guidance on the use of Pegylated interferon alfa-2a with respect to specific gender populations.
Race
There is no FDA guidance on the use of Pegylated interferon alfa-2a with respect to specific racial populations.
Renal Impairment
There is no FDA guidance on the use of Pegylated interferon alfa-2a in patients with renal impairment.
Hepatic Impairment
There is no FDA guidance on the use of Pegylated interferon alfa-2a in patients with hepatic impairment.
Females of Reproductive Potential and Males
There is no FDA guidance on the use of Pegylated interferon alfa-2a in women of reproductive potentials and males.
Immunocompromised Patients
There is no FDA guidance one the use of Pegylated interferon alfa-2a in patients who are immunocompromised.
Administration and Monitoring
Administration
There is limited information regarding Pegylated interferon alfa-2a Administration in the drug label.
Monitoring
There is limited information regarding Pegylated interferon alfa-2a Monitoring in the drug label.
IV Compatibility
There is limited information regarding the compatibility of Pegylated interferon alfa-2a and IV administrations.
Overdosage
There is limited information regarding Pegylated interferon alfa-2a overdosage. If you suspect drug poisoning or overdose, please contact the National Poison Help hotline (1-800-222-1222) immediately.
Pharmacology
There is limited information regarding Pegylated interferon alfa-2a Pharmacology in the drug label.
Mechanism of Action
There is limited information regarding Pegylated interferon alfa-2a Mechanism of Action in the drug label.
Structure
There is limited information regarding Pegylated interferon alfa-2a Structure in the drug label.
Pharmacodynamics
There is limited information regarding Pegylated interferon alfa-2a Pharmacodynamics in the drug label.
Pharmacokinetics
There is limited information regarding Pegylated interferon alfa-2a Pharmacokinetics in the drug label.
Nonclinical Toxicology
There is limited information regarding Pegylated interferon alfa-2a Nonclinical Toxicology in the drug label.
Clinical Studies
There is limited information regarding Pegylated interferon alfa-2a Clinical Studies in the drug label.
How Supplied
There is limited information regarding Pegylated interferon alfa-2a How Supplied in the drug label.
Storage
There is limited information regarding Pegylated interferon alfa-2a Storage in the drug label.
Images
Drug Images
{{#ask: Page Name::Pegylated interferon alfa-2a |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}
Package and Label Display Panel
{{#ask: Label Page::Pegylated interferon alfa-2a |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}
Patient Counseling Information
There is limited information regarding Pegylated interferon alfa-2a Patient Counseling Information in the drug label.
Precautions with Alcohol
Alcohol-Pegylated interferon alfa-2a interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
Brand Names
There is limited information regarding Pegylated interferon alfa-2a Brand Names in the drug label.
Look-Alike Drug Names
There is limited information regarding Pegylated interferon alfa-2a Look-Alike Drug Names in the drug label.
Drug Shortage Status
Price
References
The contents of this FDA label are provided by the National Library of Medicine.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [3]
Overview
Pegylated interferon alfa-2a (40kD) (commercial name PEGASYS) is an antiviral drug discovered at the pharmaceutical company F.Hoffmann-La Roche; it has a dual mode of action - both antiviral and on the immune system.
This drug is approved around the world for the treatment of chronic hepatitis C (including patients with HIV co-infection, cirrhosis, 'normal' levels of ALT) and has recently been approved (in the EU, U.S., China and many other countries) for the treatment of chronic hepatitis B.
Category
Antiviral
US Brand Names
Pegasys®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Overdosage | Clinical Studies | Dosage and Administration | How Supplied | Labels and Packages